Investors optimistic about continued biotech and medtech IPO resurgence in 2025
Though still below boom levels seen a few years ago, 2024 compares favourably to 2023, and signs suggest that growth will continue into 2025.
deal
Cochlear concludes Oticon Medical cochlear implant acquisition
Johnson Matthey to divest medical device business for $700m
Cytovale raises $84m in Series C funds to expand sepsis test rollout
Further Group partners with cancer clinical trial matcher Massive Bio
Laborie agrees to acquire Urotronic in $600m deal
Danaher agrees to acquire UK’s Abcam for $5.7bn
Bayer signs commercialisation deal for Mahana’s digital therapeutics range
